日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer.

靶向肿瘤细胞固有 CTRP6 仿生共递送可协同增强铁死亡和免疫激活,从而提高抗 PD-L1 免疫疗法在肺癌中的疗效

Cai Songhua, Huang Jing, Fan Hongjie, Sui Zhilin, Huang Chujian, Deng Youjun, Jia Ran, Wang Lixu, Ma Kai, Guo Xiaotong, He Jie, Zhang Baihua, Yu Zhentao

Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial

围手术期信迪利单抗联合铂类化疗治疗潜在可切除的IIIB期非小细胞肺癌的疗效和安全性(periSCOPE):一项开放标签、单臂、II期试验

Yu, Xiangyang; Huang, Chujian; Du, Longde; Wang, Chunguang; Yang, Yikun; Yu, Xin; Lin, Shengcheng; Yang, Chenglin; Zhao, Hongbo; Cai, Songhua; Wang, Zhe; Wang, Lixu; Guo, Xiaotong; Zhang, Baihua; Yu, Zhentao; He, Jie; Ma, Kai

Exploring a mutation-based signature to predict the benefits of immune checkpoint inhibitors in oncogene-addicted subsets of non-small cell lung cancer: a retrospective study

探索基于突变的特征来预测免疫检查点抑制剂对非小细胞肺癌癌基因依赖亚群的疗效:一项回顾性研究

Huang, Jing; Lei, Jinsong; Xiao, Baoyou; Kang, Wenyan; Sui, Zhilin; Deng, Youjun; Jia, Ran; Huang, Chujian; Cai, Songhua

Pembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report

帕博利珠单抗治疗SMARCA4缺陷型非小细胞肺癌:高肿瘤突变负荷和循环肿瘤细胞上程序性死亡配体1(+)表达用于实时监测:病例报告

Deng, Youjun; Huang, Yan; Cai, Songhua; Huang, Chujian; Liu, Wenyi; Jia, Ran; Sui, Zhilin; Zou, Heng; Yu, Zhentao; Guo, Xiaotong

Comprehensive analysis reveals the prognostic and immunogenic characteristics of DNA methylation regulators in lung adenocarcinoma

综合分析揭示肺腺癌 DNA 甲基化调节剂的预后和免疫原性特征

Jing Huang #, Chujian Huang #, Can Huang #, Zichang Xiang, Yao Ni, Jian Zeng, Songhua Cai

Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis

开发并进行基于微流控技术的CTC富集及下游分子分析平台的临床验证

Cai, Songhua; Deng, Youjun; Wang, Zhe; Zhu, Junyu; Huang, Chujian; Du, Longde; Wang, Chunguang; Yu, Xiangyang; Liu, Wenyi; Yang, Chenglin; Wang, Zhe; Wang, Lixu; Ma, Kai; Huang, Rui; Zhou, Xiaoyu; Zou, Heng; Zhang, Wenchong; Huang, Yan; Li, Zhi; Qin, Tiaoping; Xu, Tao; Guo, Xiaotong; Yu, Zhentao

Survival After Lobectomy vs. Sublobar Resection for Stage IA Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

肺叶切除术与肺亚叶切除术治疗IA期大细胞神经内分泌癌的生存率比较:一项基于人群的研究

Yu, Xiangyang; Zhang, Mengqi; Wang, Feifei; Guo, Xiaotong; Ma, Kai; Wang, Lixu; Zhao, Hongbo; Xiao, Hua; Huang, Chujian; Du, Longde; Jia, Ran; Yang, Yikun; Zhang, Lanjun; Yu, Zhentao

Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma

整合分析和实验,探索与肺腺癌预后不良、免疫浸润和癌症进展相关的血管生成调节因子

Cai, Songhua; Guo, Xiaotong; Huang, Chujian; Deng, Youjun; Du, Longde; Liu, Wenyi; Yang, Chenglin; Zhao, Hongbo; Ma, Kai; Wang, Lixu; He, Jie; Yu, Zhentao